Nektar Q2 net loss $52.4M, cash $290.6M, rezpegaldesleukin Phase 2b on track for H1 2025 topline

NEKTAR THERAPEUTICS

2024-Q2 EPS reported -$0.44 revenue$45,128,000

Net loss Q2 2024 $52.4M ($0.25/share) vs $51.1M ($0.27) Q2 2023; non-GAAP net loss $39.1M ($0.19).
Cash and investments $290.6M at June 30, 2024, down from $329.4M at Dec 31, 2023; runway into Q3 2026.
Revenue Q2 2024 $23.5M vs $20.5M Q2 2023; R&D expense flat at $29.7M; non-cash restructuring/impairment $13.3M.
Rezpegaldesleukin Phase 2b enrollment on track; topline data expected H1 2025 (atopic dermatitis) and mid-2025 (alopecia areata).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.